Sales and Marketing

Showing 15 posts of 11526 posts found.

Antidepressants come under FDA review again

July 4, 2005 Sales and Marketing

The FDA is conducting another review of antidepressants to determine whether the drugs increase the risk of suicidal behaviour in …

GSK excited about new vaccines

July 4, 2005 Sales and Marketing

GlaxoSmithKline has updated investors on its vaccine pipeline, with the company expecting to launch five major vaccines within as many …

Humira receives two European recommendations

June 29, 2005 Sales and Marketing

Abbott's Humira has moved closer to European approval as a first-line treatment of moderate to severe early rheumatoid arthritis in …

New products key to Schering growth

June 29, 2005 Sales and Marketing

Schering has reiterated its goal of achieving an 18% operating margin in 2006 and is predicting further growth in the …

FDA approves new HIV drug Aptivus

June 29, 2005 Sales and Marketing

Boehringer Ingelheim's new HIV drug Aptivus has been granted accelerated approval by the FDA. Aptivus (tipranavir) has been approved for …

GSK forms hypertension alliance

June 29, 2005 Sales and Marketing

GlaxoSmithKline has formed a strategic alliance with an emerging pharma company to develop and commercialise novel compounds to treat hypertension …

FDA approves first ‘ethnic’ heart drug

June 29, 2005 Research and Development, Sales and Marketing

The FDA has approved BiDil as a new treatment for heart failure in black patients, a group disproportionately affected by …

People Strategies launch

June 28, 2005 Sales and Marketing

A new company has been launched to bring people and change management expertise to companies that are not able to …

Roche’s Tarceva approaches EU approval

June 28, 2005 Sales and Marketing

Roche's new oral cancer treatment Tarceva has received a recommendation from the EMEA's advisory committee, paving the way for its …

AstraZeneca’s defeat opens door to more challenges

June 24, 2005 Sales and Marketing

Pharmaceutical companies found guilty of violating European antitrust laws can expect steeper fines than AstraZeneca, according to a leading law …

Side-effect doubts cloud future of Pargluva and Galida

June 24, 2005 Sales and Marketing

A study comparing novel treatment Pargluva with a best-selling diabetes drug has yielded some positive results for the new drug, …
The Gateway to Local Adoption Series

Latest content